Broad Antiviral activity of Carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Alen, Marijke M F ^a   de Burghgraeve, Tine ^a   Kaptein, Suzanne J F ^a   Balzarini, Jan ^a   Neyts, Johan ^a   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINOHIVIN; ANTIVIRUS AGENT; CARBOHYDRATE BINDING AGENT; CD209 ANTIGEN; MANNOSE; N ACETYLGLUCOSAMINE; PRADIMICIN S; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DENGUE; DENGUE VIRUS; GALANTHUS; GALANTHUS NIVALIS; HIPPEASTRUM HYBRID; HUMAN; HUMAN CELL; MEDICINAL PLANT; MONOCYTE; NONHUMAN; RAJI CELL; SEROTYPE; URTICA DIOICA; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS REPLICATION; CELL CULTURE; CYTOLOGY; DRUG EFFECT; VIROLOGY;

DENGUE VIRUS; GALANTHUS NIVALIS; HIPPEASTRUM; URTICA DIOICA;

ANTIVIRAL AGENTS; CELLS, CULTURED; DENDRITIC CELLS; DENGUE VIRUS; HUMANS; MONOCYTES;

EID: 79959757718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021658     Document Type: Article

References (67)

1. Mathew A, Rothman AL, (2008) Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 225: 300-313.
2. Takada A, Kawaoka Y, (2003) Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13: 387-398.
3. Mairuhu ATA, Wagenaar J, Brandjes DPM, van Gorp ECM, (2004) Dengue: an arthropod-borne disease of global importance. Eur J Clin Microbiol Infect Dis 23: 425-433.
4. Halstead SB, (2007) Dengue. Lancet 370: 1644-1652.
5. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745-748.
6. Rigau-Pérez JG, Clark GG, Gubler DJ, Reiter P, Sanders RJ, et al. (1998) Dengue and dengue haemorrhagic fever. Lancet 352: 971-977.
7. Halstead SB, (1988) Pathogenesis of dengue- challenges to molecular-biology. Science 239: 476-481.
8. Gubler DJ, (2004) The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis 27: 319-330.
9. Guy B, (2009) Immunogenicity of sanofi pasteur tetravalent dengue vaccine. J Clin Virol 46: 16-19.
10. Simmons M, Burgess T, Lynch J, Putnak R, (2010) Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396: 280-288.
11. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
12. Wu SJL, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, et al. (2000) Human skin Langerhans cells are targets of dengue virus infection. Nat Med 6: 816-820.
13. Chen YP, Maguire T, Hileman RE, Fromm JR, Esko JD, et al. (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3: 866-871.
14. Chen YC, Wang SY, King CC, (1999) Bacterial lipopolysaccharide inhibits dengue virus infection of primary human monocytes/macrophages by blockade of virus entry via a CD14-dependent mechanism. J Virol 73: 2650-2657.
15. Reyes-Del Valle J, Chavez-Salinas S, Medina F, Del Angel RM, (2005) Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J Virol 79: 4557-4567.
16. Jindadamrongwech S, Thepparit C, Smith DR, (2004) Identification of GRP 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2. Arch Virol 149: 915-927.
17. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, et al. (2003) Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. Embo Rep 4: 723-728.
18. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfherer C, Finke J, et al. (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197: 823-829.
19. Lozach PY, Burleigh L, Staropoli I, Navarro-Sanchez E, Harriague J, et al. (2005) Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem 280: 23698-23708.
20. Alen MMF, Kaptein SJF, De Burghgraeve T, Balzarini J, Neyts J, et al. (2009) Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology 387: 67-75.
21. Geijtenbeek TBH, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GCF, et al. (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
22. Pöhlmann S, Zhang J, Baribaud F, Chen ZW, Leslie G, et al. (2003) Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 77: 4070-4080.
23. Marzi A, Möller P, Hanna SL, Harrer T, Eisemann J, et al. (2007) Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR. J Infect Dis 196 (Suppl 2): S237-S246.
24. van Kooyk Y, Geijtenbeek TBH, (2003) DC-SIGN: Escape mechanism for pathogens. Nat Rev Immunol 3: 697-709.
25. Miller JL, Dewet BJM, Martinez-Pomares L, Radcliffe CM, Dwek RA, et al. (2008) The mannose receptor mediates dengue virus infection of macrophages. Plos Pathog 4: e17.
26. Banchereau J, Steinman RM, (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
27. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA, (2001) Human dendritic cells are activated by dengue virus infection: Enhancement by gamma interferon and implications for disease pathogenesis. J Virol 75: 3501-3508.
28. Balzarini J, François KO, Van Laethem K, Hoorelbeke B, Renders M, et al. (2010) Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use. Antimicrob Agents Chemother 54: 1425-1435.
29. Hoorelbeke B, Huskens D, Férir G, François KO, Takahashi A, et al. (2010) Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother 54: 3287-3301.
30. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
31. Hong PW, Nguyen S, Young S, Su SV, Lee B, (2007) Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. J Virol 81: 8325-8336.
32. Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, et al. (2001) Infection of human dendritic cells by Dengue virus causes cell maturation and cytokine production. J Immunol 166: 1499-1506.
33. Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, et al. (2009) Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology 383: 207-215.
34. Palucka AK, (2000) Dengue virus and dendritic cells. Nat Med 6: 748-749.
35. Marovich M, Grouard-Vogel G, Louder M, Eller M, Sun W, et al. (2001) Human dendritic cells as targets of dengue virus infection. J Invest Dermatol 6: 219-224.
36. Kyle JL, Beatty PR, Harris E, (2006) Dengue virus targets macrophages and dendritic cells in a mouse model of infection. Am J Trop Med Hyg 75: 316.
37. Rothman AL, Ennis FA, (1999) Immunopathogenesis of dengue hemorrhagic fever. Virology 257: 1-6.
38. Luplerdlop N, Misse D, Bray D, Deleuze V, Gonzalez JP, et al. (2006) Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. Embo Rep 7: 1176-1181.
39. Kwan WH, Helt AM, Maranon C, Barbaroux JB, Hosmalin A, et al. (2005) Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection. J Virol 79: 7291-7299.
40. Granelli-Piperno A, Pritsker A, Pack M, Shimeliovich I, Arrighi JF, et al. (2005) Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J Immunol 175: 4265-4273.
41. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, et al. (2007) Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci U S A 104: 19464-19469.
42. Lambert AA, Gilbert C, Richard M, Beaulieu AD, Tremblay MJ, (2008) The C-type lectin surface receptor DICIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 112: 1299-1307.
43. Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, et al. (2006) Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124: 485-493.
44. Stahl PD, Ezekowitz RAB, (1998) The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 10: 50-55.
45. Taylor PR, Gordon S, Martinez-Pomares L, (2005) The mannose receptor: linking homeostasis and immunity through sugar recognition. Trends Immunol 26: 104-110.
46. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D, (2007) Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol 71: 3-11.
47. Bertaux C, Daelemans D, Meertens L, Cormier EG, Reinus JF, et al. (2007) Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology 366: 40-50.
48. Pollicita M, Schols D, Aquaro S, Peumans WJ, Van Damme EJM, et al. (2008) Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4(+) T lymphocytes. Virology 370: 382-391.
49. Balzarini J, Schols D, Neyts J, Van Damme E, Peumans W, et al. (1991) Alpha-(1-3)-D-mannose-specific and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob Agents Chemother 35: 410-416.
50. Balzarini J, Van Damme L, (2007) Microbicide drug candidates to prevent HIV infection. Lancet 369: 787-797.
51. Kou Z, Quinn M, Chen HY, Rodrigo WW, Rose RC, et al. (2008) Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol 80: 134-146.
52. Tanaka H, Chiba H, Inokoshi J, Kuno A, Sugai T, et al. (2009) Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci U S A 106: 15633-15638.
53. Luallen RJ, Fu H, Agrawal-Gamse C, Mboudjeka I, Huang W, et al. (2009) A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. J Virol 83: 4861-4870.
54. François KO, Auwerx J, Schols D, Balzarini J, (2008) Simian immunodeficiency virus is susceptible to inhibition by carbohydrate-binding agents in a manner similar to that of HIV: Implications for further preclinical drug development. Mol Pharmacol 74: 330-337.
55. Balzarini J, Neyts J, Schols D, Hosoya M, Van Damme E, et al. (1992) The mannose-specific plant lectins from Cymbidium hybrid and Epipactis-helleborine and the (N-acetylglucosamine) N-specific plant lectin from Urtica-dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res 18: 191-207.
56. Hacker K, White L, de Silva AM, (2009) N-Linked glycans on dengue viruses grown in mammalian and insect cells. J Gen Virol 90: 2097-2106.
57. Rogers KM, Heise M, (2009) Modulation of cellular tropism and innate antiviral response by viral glycans. J Innate Immun 1: 405-412.
58. Relloso M, Puig-Kröger A, Pello OM, Rodriguez-Fernandez JL, de la Rosa G, et al. (2002) DC-SIGN (CD209) expression is IL-4 dependent and is negatively regulated by IFN, TGF-beta, and anti-inflammatory agents. J Immunol 168: 2634-2643.
59. Tacken PJ, de Vries IJM, Torensma R, Figdor CG, (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7: 790-802.
60. Palmer DR, Sun PF, Celluzzi C, Bisbing J, Pang SN, et al. (2005) Differential effects of dengue virus on infected and bystander dendritic cells. J Virol 79: 2432-2439.
61. Dejnirattisai W, Duangchinda T, Lin CLS, Vasanawathana S, Jones M, et al. (2008) A complex interplay among virus, dendritic cells, T cells, and cytokines in Dengue virus infections. J Immunol 181: 5865-5874.
62. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, et al. (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101: 758-765.
63. Van Damme E, Allen A, Peumans W, (1987) Isolation and characterization of a lectin with exclusive specificity towards mannose from snowdrop (Galanthus nivalis) bulbs. FEBS Lett 251: 140-144.
64. Van Damme E, Kaku H, Perini F, Goldstein I, Peeters B, et al. (1991) Biosynthesis, primary structure and molecular cloning of snowdrop (Galanthus Nivalis L.) lectin. FEBS Lett 202: 23-30.
65. Saitoh K, Tsuno T, Kakushima M, Hatori M, Furumai T, et al. (1993) Pradimicin-S, a new pradimicin analog. II. Isolation and structure elucidation. J Antibiot 46: 406-411.
66. Chiba H, Inokoshi J, Okamoto M, Asanuma S, Matsuzaki K, et al. (2001) Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: Isolation, characterization, and biological activities. Biochem Biophys Res Commun 282: 595-601.
67. Irie K, Mohan PM, Sasaguri Y, Putnak R, Padmanabhan R, (1989) Sequence-analysis of cloned dengue virus type-2 genome (New-guinea-C strain). Gene 75: 197-211.